We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Ribociclib Plus Letrozole Shows Potent Activity in Recurrent Low-Grade Serous Ovarian Carcinoma: Results from GOG 3026

MedXY Editorial Team•Jan 19, 2026•news
CDK4/6 inhibitorsGynecologic OncologyRibociclib

Highlights

Targeted Synergy

The combination of the CDK4/6 inhibitor ribociclib and the aromatase inhibitor letrozole leverages the hormonal and molecular drivers of low-grade serous carcinoma (LGSOC), achieving an objective response rate of 30.6% and a clinical benefit rate of 84%.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

No Time to Waste: Addressing Diagnostic Delays in Vulvar Squamous Cell CarcinomaThis article reviews a study identifying key factors contributing to delays in diagnosing vulvar squamous cell carcinoma, emphasizing provider and system-level influences and the need for timely biopsy and specialist referrals.Aug 25, 2026Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groupsThis review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.Aug 22, 2026Enhancing Patient Engagement in Gynecologic Oncology Clinical Trials Through a Pilot Patient Ambassador ProgramA pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.Aug 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Enhanced Gynecologic Oncology Decision Support: Impact of Guideline-Anchored Retrieval-Augmented Generation Versus Baseline and Literature-Based AI Models
A study benchmarking large language models in gynecologic oncology demonstrates that guideline-anchored retrieval-augmented generation (RAG) configurations outperform baseline and literature-only AI systems in clinical decision support, hig
Aug 18, 2026
Unraveling Failure to Rescue in Major Gynecologic Cancer Surgery: Insights from a NSQIP AnalysisThis study identifies key patient-level factors associated with failure to rescue after major gynecologic oncology surgery, emphasizing complication severity and physiological reserve over procedure complexity.Aug 18, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative SynthesisThis review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.May 26, 2026